医学
淋巴结
纵隔淋巴结
肺癌
解剖(医学)
放射科
淋巴
纵隔
磨玻璃样改变
放射性武器
病态的
肺
癌症
病理
转移
内科学
腺癌
作者
Tomohiro Maniwa,Jiro Okami,Tomohiro Miyoshi,Masashi Wakabayashi,Hiroshige Yoshioka,Takahiro Mimae,Makoto Endoh,Aritoshi Hattori,Kazuo Nakagawa,Tetsuya Isaka,Mitsuhiro Isaka,Ryuichi Kita,Yuta Sekino,noriko mitome,Keiju Aokage,Hisashi Saji,Ryu Nakajima,Morihito Okada,Masahiro Tsuboi,Hisao Asamura,Haruhiko Fukuda,Shun‐ichi Watanabe
标识
DOI:10.1016/j.jtcvs.2023.11.023
摘要
ABSTRACT
Objective
The optimal region of lymph node dissection (LND) during segmentectomy in patients with small peripheral non-small cell lung cancer requires clarification. Through a supplemental analysis of the JCOG0802/WJOG4607L, we investigated the associated factors, distribution, and recurrence pattern of lymph node metastases (LNM) and proposed the optimal LND region. Methods
Of the 1106 patients included in the JCOG0802/WJOG4607L, 1056 patients with LNDs were included in this supplemental analysis. We investigated the distribution and recurrence pattern of LNMs along with the radiological findings (with ground glass opacity [GGO], part-solid tumor; without GGO component, pure-solid tumor). Results
The radiological findings were the only significant factor for LNMs. Of 533 patients with part-solid tumors, eight (1.5%) had LNMs. Further, only three (0.5%) patients had pN2 disease, and no patients had interlobar LNMs from non-adjacent segments. Of the 523 patients with pure-solid tumors, 55 (10.5%) had LNMs, and 28 (5.4%) had pN2 disease. Five patients had metastases to non-adjacent interlobar lymph nodes (LNs). Two (2.0%) patients with S6 tumors had upper mediastinal LNMs. In addition, the incidence of mediastinal LN recurrence in patients with S6 lung cancer was greater in those who underwent selective LND than those who underwent systematic LND (p = 0.0455). Conclusions
Non-adjacent interlobar and mediastinal LND have little impact on pathological nodal staging in patients with part-solid tumors. In contrast, selective LND is recommended at least for patients with pure-solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI